Rolf Weitkunat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rolf Weitkunat has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Peter Nicholas Lee
P.N. Lee Statistics and Computing Ltd., Sutton, UK
3 shared publications - Gerd Kallischnigg
Department of Biostatistics & Epidemiology, R&D, Philip Morris International, Neuchâtel, Switzerland
2 shared publications - Edward Sanders
PMI Research & Development, Philip Morris Products S.A., Neuchâtel, Switzerland
1 shared publication - Etienne Kaelin
Department of Biostatistics & Epidemiology, R&D, Philip Morris International, Neuchâtel, Switzerland
1 shared publication - Grégory Vuillaume
Department of Biostatistics & Epidemiology, R&D, Philip Morris International, Neuchâtel, Switzerland
1 shared publication - Zheng Sponsiello-Wang
Philip Morris Products S.A, PMI Research & Development, Neuchâtel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 28 May 2010
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 10 (1) , 47
Effectiveness of strategies to increase the validity of findings from association studies: size vs. replication
The capacity of multiple comparisons to produce false positive findings in genetic association studies is abundantly clear. To address this issue, the concept of false positive report probability (FPRP) measures "the probability of no true association between a genetic variant and disease given a statistically significant finding". This concept involves the notion of prior probability of an association between a genetic variant and a disease, making it difficult to achieve acceptable levels for the FPRP when the prior probability is low. Increasing the sample size is of limited efficiency to improve the situation.
- 28 May 2010
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 10 (1) , 47
Open AccessEffectiveness of strategies to increase the validity of findings from association studies: size vs. replication
The capacity of multiple comparisons to produce false positive findings in genetic association studies is abundantly clear. To address this issue, the concept of false positive report probability (FPRP) measures "the probability of no true association between a genetic variant and disease given a statistically significant finding". This concept involves the notion of prior probability of an association between a genetic variant and a disease, making it difficult to achieve acceptable levels for the FPRP when the prior probability is low. Increasing the sample size is of limited efficiency to improve the situation.
- Open Access
- 1 December 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 356
Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America
Background: Recent reviews claiming smokeless tobacco increases pancreatic cancer risk appear not to have considered all available epidemiological evidence; nor were meta-analyses included. We present a systematic review of studies from North America and Europe, since data are lacking from other continents. Risk is also difficult to quantify elsewhere due to the various products, compositions and usage practices involved. Methods: Epidemiological studies were identified that related pancreatic cancer to use of snuff, chewing tobacco or unspecified smokeless tobacco. Study details and effect estimates (relative risks or odds ratios) were extracted, and combined by meta-analyses. Results: Nine North American and two Scandinavian studies were identified. Reporting was limited in four studies, so only seven were included in meta-analyses, some providing results for never smokers, some for the overall population of smokers and non-smokers, and some for both. Giving preference to study-specific estimates for the overall population, if available, and for never smokers otherwise, the random-effects estimate for ever smokeless tobacco use was 1.03 (95% confidence interval 0.71–1.49) based on heterogeneous estimates from seven studies. The estimate varied little by continent, study type, or type of smokeless tobacco. Giving preference to estimates for never smokers, if available, and overall population estimates otherwise, the estimate was 1.14 (0.67–1.93), again based on heterogeneous estimates. Estimates varied (p = 0.014) between cohort studies (1.75, 1.20–2.54) and case-control studies (0.84, 0.36–1.97). The value for cohort studies derived mainly from one study, which reported an increase for never smokers (2.0, 1.2–3.3), but not overall (0.9, 0.7–1.2). This study also contributed to increases seen for snuff use and for European studies, significant only in fixed-effect analyses. The studies have various weaknesses, including few exposed cases, reliance in cohort studies on exposure recorded at baseline, poor control groups in some case-control studies, and lack of a dose-response. Publication bias, with some negative studies not being presented, is also possible. Conclusion: At most, the data suggest a possible effect of smokeless tobacco on pancreatic cancer risk. More evidence is needed. If any risk exists, it is highly likely to be less than that from smoking.
- 1 December 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 356
Open AccessSystematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America
Background: Recent reviews claiming smokeless tobacco increases pancreatic cancer risk appear not to have considered all available epidemiological evidence; nor were meta-analyses included. We present a systematic review of studies from North America and Europe, since data are lacking from other continents. Risk is also difficult to quantify elsewhere due to the various products, compositions and usage practices involved. Methods: Epidemiological studies were identified that related pancreatic cancer to use of snuff, chewing tobacco or unspecified smokeless tobacco. Study details and effect estimates (relative risks or odds ratios) were extracted, and combined by meta-analyses. Results: Nine North American and two Scandinavian studies were identified. Reporting was limited in four studies, so only seven were included in meta-analyses, some providing results for never smokers, some for the overall population of smokers and non-smokers, and some for both. Giving preference to study-specific estimates for the overall population, if available, and for never smokers otherwise, the random-effects estimate for ever smokeless tobacco use was 1.03 (95% confidence interval 0.71–1.49) based on heterogeneous estimates from seven studies. The estimate varied little by continent, study type, or type of smokeless tobacco. Giving preference to estimates for never smokers, if available, and overall population estimates otherwise, the estimate was 1.14 (0.67–1.93), again based on heterogeneous estimates. Estimates varied (p = 0.014) between cohort studies (1.75, 1.20–2.54) and case-control studies (0.84, 0.36–1.97). The value for cohort studies derived mainly from one study, which reported an increase for never smokers (2.0, 1.2–3.3), but not overall (0.9, 0.7–1.2). This study also contributed to increases seen for snuff use and for European studies, significant only in fixed-effect analyses. The studies have various weaknesses, including few exposed cases, reliance in cohort studies on exposure recorded at baseline, poor control groups in some case-control studies, and lack of a dose-response. Publication bias, with some negative studies not being presented, is also possible. Conclusion: At most, the data suggest a possible effect of smokeless tobacco on pancreatic cancer risk. More evidence is needed. If any risk exists, it is highly likely to be less than that from smoking.
- Open Access
- 1 May 2008
- Published by Springer Nature in BMC Oral Health
- Vol. 8 (1) , 13
Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States
How smokeless tobacco contributes to non-neoplastic oral diseases is unclear. It certainly increases risk of oral mucosal lesions, but reviewers disagree as to other conditions. In some areas, especially South-East Asia, risk is difficult to quantify due to the many products, compositions (including non-tobacco ingredients), and usage practices involved. This review considers studies from Europe (in practice mainly Scandinavia) and from the USA.
- 1 May 2008
- Published by Springer Nature in BMC Oral Health
- Vol. 8 (1) , 13
Open AccessSystematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States
How smokeless tobacco contributes to non-neoplastic oral diseases is unclear. It certainly increases risk of oral mucosal lesions, but reviewers disagree as to other conditions. In some areas, especially South-East Asia, risk is difficult to quantify due to the many products, compositions (including non-tobacco ingredients), and usage practices involved. This review considers studies from Europe (in practice mainly Scandinavia) and from the USA.
- Open Access
- 15 November 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 334
Meta-analysis of the relation between European and American smokeless tobacco and oral cancer
Smokeless tobacco is often referred to as a major contributor to oral cancer. In some regions, especially Southeast Asia, the risk is difficult to quantify due to the variety of products, compositions (including non-tobacco ingredients) and usage practices involved. In Western populations, the evidence of an increased risk in smokeless tobacco users seems unclear, previous reviews having reached somewhat differing conclusions. We report a detailed quantitative review of the evidence in American and European smokeless tobacco users, and compare our findings with previous reviews and meta-analyses.
- 15 November 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 334
Open AccessMeta-analysis of the relation between European and American smokeless tobacco and oral cancer
Smokeless tobacco is often referred to as a major contributor to oral cancer. In some regions, especially Southeast Asia, the risk is difficult to quantify due to the variety of products, compositions (including non-tobacco ingredients) and usage practices involved. In Western populations, the evidence of an increased risk in smokeless tobacco users seems unclear, previous reviews having reached somewhat differing conclusions. We report a detailed quantitative review of the evidence in American and European smokeless tobacco users, and compare our findings with previous reviews and meta-analyses.